Arvoella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. Arvoella’s lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. Arvoella is also expanding into solid tumour treatment through its CLDN18.2-targeting technology licensed from Sparx Group. iNKT cells also contain an invariant T cell receptor (iTCR) that targets α-GalCer bound CD1d, another antigen found on the surface of several cancer types. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient.
Arovella Therapeutics Limited (ASX:ALA)
Realising the Potential of Invariant Natural Killer T (iNKT) Cell Therapy
About Us
Arovella Therapeutics is a biotechnology company focused on leveraging its proprietary invariant Natural Killer T (iNKT) cell therapy platform from Imperial College London to address the treatment needs for both blood cancers and solid tumours.
Latest News
ASX Health Stocks: LBT skyrockets 40pc after winning deal with global pharma, AstraZeneca
7th August 2024
Arovella Therapeutics moves toward IND for ALA-101 lymphoma and leukaemia trials with positive FDA feedback
7th August 2024
Arovella Therapeutics prepares for key clinical milestones in cancer treatment
28th July 2024